IDEXX Lifts Outlook on Q2 Growth, Innovation

IDEXX Laboratories reported strong second-quarter 2025 results, with revenue rising 11% year-over-year to $1.11 billion and EPS climbing nearly 49% to $3.63, exceeding analyst estimates. Performance was fueled by robust growth in the Companion Animal Group and rapid adoption of new diagnostic products, notably the inVue Dx device, which saw higher-than-expected placements at veterinary clinics. Following the results, IDEXX raised its full-year 2025 EPS outlook to $12.40–$12.76 and revenue guidance to as much as $4.28 billion, citing strong customer demand and international momentum. The company's shares surged between 9% and 28% after the earnings announcement, reflecting investor confidence. While IDEXX faces ongoing labor shortages in animal hospitals and foreign exchange headwinds, its adoption of cloud-based veterinary software is strengthening client loyalty. Analysts remain positive about IDEXX’s long-term prospects, pointing to consistent earnings surprises and a strategic focus on product innovation and IT solutions.